Therapeutics News and Research

RSS

MRSA study suggests strategy shift needed to develop effective therapeutics

USA300-the major epidemic strain of methicillin-resistant Staphylococcus aureus (MRSA) causing severe infections in the United States during the past decade-inherits its destructiveness directly from a forefather strain of the bacterium called USA500 rather than randomly acquiring harmful genes from other MRSA strains.

17 Mar 2009

Lung cancer: Molecular scissors determine therapy effectiveness

In the past few years, a number of anti-cancer drugs have been developed which are directed selectively against specific key molecules of tumor cells.

17 Mar 2009

Intradigm receives notice of allowance for key RNA interference patent covering potent siRNA sequence

Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, has announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance for a patent covering various aspects of a potent small interfering RNA (siRNA) sequence.

17 Mar 2009

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

Arno Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug ("IND") application for the use of AR-42.

17 Mar 2009

Alba Therapeutics announces next clinical trial of lead compound, Larazotide Acetate

Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.

17 Mar 2009

Discovery of new mechanism for the processing of endocannabinoids

New research funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, has identified a new mechanism for the processing of endocannabinoids, natural brain compounds similar to THC, the active ingredient in marijuana.

17 Mar 2009

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009

ADMEcell enters into manufacturing and distribution agreement with Advancell

ADMEcell, announced that it has entered into an exclusive agreement with Advancell, Barcelona, Spain, to manufacture and distribute the CacoReady System for the North American market.

15 Mar 2009

A model of melanoma generates hope for the use of targeted therapies

Researchers have developed a new mouse model that allows them to replicate normal pigment cells at the earliest stages of conversion to malignant skin cancer in humans.

12 Mar 2009

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Azaya Therapeutics, Inc. has announced that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Azaya's lead cancer therapy, ATI - 1123.

10 Mar 2009

Challenge of a cure for HIV infection

A group including leading academic and industry scientists has issued a challenge to researchers in the field of HIV/AIDS: find a way to effectively purge latent HIV infection and eliminate the need for chronic, suppressive therapy to control this disease.

5 Mar 2009

Three biomarkers found for Chikungunya fever

Three specific biomarkers provide an accurate indication of the severity of Chikungunya fever (CHIKF), which is emerging as a threat in South-East Asia, the Pacific and Europe, according to research conducted in Singapore.

4 Mar 2009

Type 1 diabetes patients sought for UT Southwestern clinical drug trial

UT Southwestern Medical Center researchers are recruiting individuals newly diagnosed with type 1 diabetes for a clinical trial to gauge the effectiveness of adding an investigational stem cell product to standard insulin therapy.

3 Mar 2009

Instant immunity through chemically programmable vaccination and covalent self-assembly

The experiments, thus far performed only in mice, appear to overcome a major drawback of vaccinations - the lag time of days, or even weeks, that it normally takes for immunity to build against a pathogen.

2 Mar 2009

Experimental drug fampridine improves mobility for some MS patients

In MS, the body's immune system attacks myelin, a fatty tissue that wraps and insultates nerve fibers, disrupting the transmission of signals in the central nervous system.

1 Mar 2009

New software aids discovery of new genetic markers for diseases

Modern genotyping technologies offer new opportunities to explore how genes influence health and disease, but also present the challenge of analyzing huge amounts of genetic and clinical data.

26 Feb 2009

Human stem cells provide a new model for Lou Gehrig's disease

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a devastating condition in which motor neuron degeneration causes progressive loss of movement and muscle tone, leading to death.

23 Feb 2009

Gold nanoparticles improve gene regulation

Investigators at Northwestern University have found that packing small interfering RNA (siRNA) molecules onto the surface of a gold nanoparticle can protect siRNAs from degradation and increase their ability to regulate genes involved in cancer. As a result of this discovery, cancer researchers have at their disposal a relatively straightforward method of delivering these potent gene-regulating agents into targeted cells.

23 Feb 2009

Microfluidic device mimics tumor microenvironment, helps drug discovery

One of the challenges that cancer researchers face in designing new antitumor agents is that of predicting how drug molecules will behave in the complex microenvironment that surrounds a tumor. In particular, tumors create all sorts of chemical and physical barriers that limit how much drug is able to enter a tumor, let alone reach cells deep within a tumor.

23 Feb 2009

Presence of a biomarker in regional lymph nodes predicts disease recurrence in colorectal cancer

Findings published in the Journal of the American Medical Association by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurrence in patients with colorectal cancer.

18 Feb 2009